Trial Profile
Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs SRX 246 (Primary)
- Indications Anxiety disorders
- Focus Proof of concept; Therapeutic Use
- 01 Sep 2021 Results published in the Psychopharmacology
- 20 Jul 2019 Status changed from recruiting to completed.
- 03 Nov 2018 Planned End Date changed from 31 Dec 2019 to 31 Dec 2030.